A novel vaccine against Neisseria gonorrhoeae

Applications: Vaccines

A new strain of gonococcus, produced by replacing the native PorB with analogs from another bacterium to enhance immunogenicity, as new generation outer membrane vesicle (OMV) vaccine.

Features	Benefits
Simple replacement of Neisseria gonorrhaeae porB gene with Neisseria Meningitidis porB gene	Enhances immunogenicity whilst maintains viability of Neisseria gonorrhoeae
§Deletion of RmpM gene	Increases OMV production which is a key component of OMV vaccines

Patented and available for:

Licensing
Co-development
Consulting

Request more information
about this technology

Back to Technologies Available

Technologies for License

A novel vaccine against Neisseria gonorrhoeae

Ready to get in touch?